Long-Term Exposure to Low-Dose Prednisone With Abiraterone Acetate for mCRPC

May 21, 2015
Leonard Gomella, MD

Special Reports, Genitourinary (Issue 2), Issue 2

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

<<<

View more from the GU Cancers Special Report